Search Results

Search here to find what you are looking for.  If you are searching for a Teva product, you may want to try searching in one of our product catalogues or feel free to contact us for assistance.

Showing 10 from 14 results

Important safety information on prescription cough and cold products containing opioids and the risk of opioid ase disorder in children and adolescents

Teva Canada announces product availability of AJOVY™

CGPA releases blueprint for a sustainable supply of prescription medicines for Canadians

Teva Canada secures Salbutamol Inhalers from its global supply chain to mitigate shortage in Canadian market

Availability of UK-Labelled Product – Salbutamol Metered Dose Inhaler (MDI)

Important Safety Information - Importation of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler due to Shortage

Teva Canada announces the launch of AJOVY™ for the preventive treatment of migraine in adults who have at least four migraine days per month

COVID-19 is increasing the number of Canadians requiring caregiver information and support. Learn about how to protect yourself and others in the home, as well as those in your community

Teva Canada announces the launch of a Bioequivalent Generic Version of Gilenya®, Teva-Fingolimod Capsulesfor the treatment of Relapsing-Remitting Multiple Sclerosis (MS)

Teva Canada announces the Approval of HERZUMA®, a biosimilar to HERCEPTIN® for the treatment of adult patients with Early Breast Cancer, Metastatic Breast Cancer and Metastatic Gastric Cancer.
This is the second Notice of Compliance (NOC) issued for a biosimilar in 2019 that Teva Canada Innovation will add to its portfolio of brands, generics and biosimilars.